NSETrading Window29 Jun 2026 · 29 Jun 2026, 04:47 pm

Trading Window

Piramal Pharma Limited · PPLPHARMA

✦ AI SummaryRegulatory

Piramal Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Analysis Scores

Earnings Impact5/10
Growth Catalyst5/10
Governance Concern2/10
Regulatory Risk8/10
Balance Sheet Risk5/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Piramal Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Attachments (1)

📄

PIRAMALPHARMA_29062026164700_SEIntimation_Window_closure.pdf

pdf

Download →
View document text
29th June, 2026 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Subject: Intimation of closure of trading window Dear Sir / Madam, Pursuant to the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and in terms of the Company’s Code of Conduct to regulate, monitor and report trading by Designated Persons (‘the Code’), we wish to inform you that the Trading Window for dealing in securities of Piramal Pharma Limited shall remain closed for all Designated Persons and their immediate relatives covered under the Code from Wednesday, July 1, 2026 until 48 hours after declaration of the unaudited financial results of the Company for the quarter ending June 30, 2026. The date of the Board Meeting to approve the said financial results, shall be communicated in due course. Kindly take the above on record. Thank you. Yours truly, For Piramal Pharma Limited Maneesh Sharma Company Secretary & Compliance Officer Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India Tel No. +91 22 3802 3000 / 4000; Email Id: shareholders.ppl@piramal.com www.piramalpharma.com